NCT01697618 - Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 1997

Primary Completion Date

November 30, 1998

Study Completion Date

November 30, 1998

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

biphasic insulin aspart 30

Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs

DRUG

biphasic human insulin 30

Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs

Trial Locations (2)

Novo Nordisk Investigational Site, Alphen aan den Rijn

Novo Nordisk Investigational Site, Crawley